Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Should Let Alzheimer’s Trials Rely On Single Endpoint, Group Says

Executive Summary

Informally, FDA appears open to trials that use cognition as the only primary endpoint rather than insisting that products also show benefit on the functional side.

Advertisement

Related Content

Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Alzheimer's Endpoint ADAS-Cog Likely Here To Stay Despite Clinical Failures
A New Direction for Alzheimer’s R&D: FDA Outlines Early Disease Pathway

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel